All the news Showing 10 of 135 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B Keith Alcorn / 14 November 2022 The experimental hepatitis B antiviral VIR-2218 shows potent activity against the virus when combined with either a monoclonal antibody that targets three steps in the hepatitis B lifecycle, or pegylated interferon, two studies ... Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five Keith Alcorn / 14 November 2022 Up to one in five people with hepatitis B treated with the experimental antiviral bepirovirsen achieved a sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA, a sign indicating the ... Biktarvy combination pill may be most effective option for people with HIV and hepatitis B Liz Highleyman / 03 August 2022 Although two antiretroviral drug regimens proved about equally effective at suppressing HIV, the Biktarvy combination pill (bictegravir, emtricitabine and tenofovir alafenamide) did a better job suppressing hepatitis B virus (HBV) ... Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Keith Alcorn / 29 June 2022 Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ... Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... Hepatitis B treatment for all who need it an "achievable public health goal" for Malawi Keith Alcorn / 13 December 2021 Providing hepatitis B treatment for everyone who needs it in Malawi is an achievable public health goal, researchers from the Malawi-Liverpool-Wellcome Trust programme report, following community surveys in Blantyre, Malawi. Hepatitis B treatment ... People with HIV and hepatitis B should have ongoing monitoring for liver cancer Liz Highleyman / 15 March 2021 People with HIV and hepatitis B co-infection remain at risk for developing hepatocellular carcinoma (HCC) despite antiviral treatment and should undergo regular monitoring for liver cancer, according to research presented ... Major hep B players Gilead and Vir join forces to find a cure Fierce Biotech / 18 January 2021 2.5 million people in Africa need urgent hepatitis B treatment Keith Alcorn / 09 December 2020 Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ... Some hepatitis B patients can safely stop antivirals Liz Highleyman / 24 November 2020 Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ... ← First12345...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive